{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:25:27Z","timestamp":1781375127658,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"am","delay-in-days":307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007786","name":"National Center for Child Health and Development","doi-asserted-by":"publisher","award":["26A-20"],"award-info":[{"award-number":["26A-20"]}],"id":[{"id":"10.13039\/100007786","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["15Ack016152h0001"],"award-info":[{"award-number":["15Ack016152h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ck0106434h0003"],"award-info":[{"award-number":["20ck0106434h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.humpath.2021.07.011","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T18:41:23Z","timestamp":1628102483000},"page":"112-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan"],"prefix":"10.1016","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7755-9676","authenticated-orcid":false,"given":"Hideto","family":"Iwafuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-4281","authenticated-orcid":false,"given":"Atsuko","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Sekimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Iijima-Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2838-4555","authenticated-orcid":false,"given":"Kentaro","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Kiyokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiji","family":"Fukano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko M.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Horibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2021.07.011_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"413","article-title":"Anaplastic large cell lymphoma, ALK-positive","author":"Falini","year":"2017"},{"key":"10.1016\/j.humpath.2021.07.011_bib2","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.V97.12.3699","article-title":"Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-M\u00fcnster Group Trial NHL-BFM 90","volume":"97","author":"Seidemann","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.07.011_bib3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group","volume":"27","author":"Brugi\u00e8res","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.07.011_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1008352726155","article-title":"Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology","volume":"11","author":"Brugi\u00e8res","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2021.07.011_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2141.2005.05910.x","article-title":"Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan","volume":"132","author":"Mori","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2021.07.011_bib6","doi-asserted-by":"crossref","first-page":"44960","DOI":"10.18632\/oncotarget.16680","article-title":"Mechanisms of PD-1\/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies","volume":"8","author":"Gravelle","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2021.07.011_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2021.07.011_bib8","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.humpath.2021.07.011_bib9","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2021.07.011_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2021.07.011_bib11","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","article-title":"B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.07.011_bib12","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2010.28.5999","article-title":"Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial","volume":"28","author":"Le Deley","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.07.011_bib13","first-page":"526","article-title":"Analysis of Japanese registration from the randomized international trial for childhood anaplastic large cell lymphoma (ALCL99-R1)","volume":"55","author":"Mori","year":"2014","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.humpath.2021.07.011_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12185-017-2338-6","article-title":"Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma","volume":"107","author":"Iijima-Yamashita","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.humpath.2021.07.011_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.humpath.2021.07.011_bib16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/leu.2012.205","article-title":"Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis","volume":"27","author":"Mussolin","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2021.07.011_bib17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41379-019-0336-3","article-title":"PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma","volume":"33","author":"Shen","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2021.07.011_bib18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00000478-199309000-00001","article-title":"A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma","volume":"17","author":"Kinney","year":"1993","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2021.07.011_bib19","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1200\/JCO.2011.36.5411","article-title":"Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study","volume":"29","author":"Lamant","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.07.011_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2007-02-066852","article-title":"Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma","volume":"110","author":"Damm-Welk","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.07.011_bib21","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2009-11-251892","article-title":"Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk","volume":"115","author":"Ait-Tahar","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.07.011_bib22","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2007-07-100958","article-title":"Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study","volume":"111","author":"Le Deley","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.07.011_bib23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3324\/haematol.2013.085837","article-title":"Expression of CD8 is associated with non-common type morphology and outcome in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","volume":"98","author":"Abramov","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2021.07.011_bib24","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Canc Res"},{"key":"10.1016\/j.humpath.2021.07.011_bib25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2016-05-717793","article-title":"Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target","volume":"129","author":"Werner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.07.011_bib26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/pin.12259","article-title":"Role of tumor-associated macrophages in hematological malignancies","volume":"65","author":"Komohara","year":"2015","journal-title":"Pathol Int"},{"key":"10.1016\/j.humpath.2021.07.011_bib27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","article-title":"Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy","volume":"103","author":"de Charette","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2021.07.011_bib28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2017.177972","article-title":"Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma","volume":"103","author":"Kn\u00f6rr","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2021.07.011_bib29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/his.12407","article-title":"High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma","volume":"65","author":"Pedersen","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2021.07.011_bib30","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","article-title":"PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer","volume":"22","author":"Zhang","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.07.011_bib31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.humpath.2021.07.011_bib32","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/biom10081087","article-title":"Significance of immunosuppressive cells as a target for immunotherapies in melanoma and non-melanoma skin cancers","volume":"10","author":"Fujimura","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.humpath.2021.07.011_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26902","article-title":"Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma","volume":"65","author":"Rigaud","year":"2018","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.humpath.2021.07.011_bib34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7326\/L16-0037","article-title":"Nivolumab for refractory anaplastic large cell lymphoma: a case report","volume":"165","author":"Hebart","year":"2016","journal-title":"Ann Intern Med"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817721001325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817721001325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:39:12Z","timestamp":1758645552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817721001325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":34,"alternative-id":["S0046817721001325"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2021.07.011","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2021.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}